Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 3:47 p.m.

    📋 Arbutus Biopharma Corporation (ABUS) - Clinical Trial Update

    Filing Date: 2022-07-20

    Accepted: 2022-07-20 16:12:18

    Event Type: Clinical Trial Update

    Event Details:

    Arbutus Biopharma Corporation (ABUS) Announces Clinical Trial Update Arbutus Biopharma Corporation (ABUS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, patients
    • Diseases/Conditions: chronic
    • Clinical Stage: clinical trial
    • Collaboration: the Phase 2A Combination Trial
      • expected in the second half of 2022
      • expected in 2H 2022

    🔬 Clinical Development Pipeline (Arbutus Biopharma Corporation):

    Product Type Development Stage Therapeutic Area Source
    Nucleos(t)ide Analogue DRUG Phase PHASE1 Chronic Hepatitis ClinicalTrials.gov
    Imdusiran (AB-729) DRUG Phase PHASE2 Chronic Hepatitis B ClinicalTrials.gov
    AB-729 DRUG Phase PHASE2 Chronic Hepatitis b ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Hypercholesterolemia ClinicalTrials.gov
    PRO-040201 DRUG Phase PHASE1 Hypercholesterolemia ClinicalTrials.gov
    TKM-100802 for Injection DRUG Phase PHASE1 Ebola Virus Infection ClinicalTrials.gov
    TKM-100201 DRUG Phase PHASE1 Ebola Virus Infection ClinicalTrials.gov
    ARB-001467 DRUG Phase PHASE2 Hepatitis B, Chronic ClinicalTrials.gov
    L-DOS47 DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    TKM-080301 DRUG Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    AB-836 DRUG Phase PHASE1 Chronic Hepatitis ClinicalTrials.gov
    Durvalumab DRUG Phase PHASE2 Hepatitis B, Chronic ClinicalTrials.gov
    Imdusiran DRUG Phase PHASE2 Hepatitis B, Chronic ClinicalTrials.gov
    AB-101 DRUG Phase PHASE1 Chronic Hepatitis b ClinicalTrials.gov
    Non-interventional OTHER Preclinical Long Term Follow-up ClinicalTrials.gov
    Peg-IFNα-2a DRUG Phase PHASE2 Chronic Hepatitis b ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Arbutus Biopharma Corporation
    • CIK: 0001447028
    • Ticker Symbol: ABUS
    • Period End Date: 2022-07-20
    • Document Type: 8-K

Search

News categories